Novel SLC12A3 mutation in Gitelman syndrome

BMJ Case Rep. 2021 Jan 18;14(1):e238097. doi: 10.1136/bcr-2020-238097.

Abstract

Gitelman syndrome (GS) is an autosomal recessive disease characterised by the presence of hypokalaemic metabolic alkalosis with hypomagnesaemia and hypocalciuria. The prevalence of this disease is 1-10/40 000. GS is usually associated with mild and non-specific symptoms and many patients are only diagnosed in adulthood. The disease is caused by mutations in the SLC12A3 gene. We present the case of a 49-year-old man referred to a nephrology appointment due to persistent hypokalaemia and hypomagnesaemia. Complementary evaluation revealed hypokalaemia, hypomagnesaemia, metabolic alkalosis, hyperreninaemia, increased chloride and sodium urinary excretion, and reduced urinary calcium excretion. Renal function, remainder serum and urinary ionogram, and renal ultrasound were normal. A diagnosis of GS was established and confirmed with genetic testing which revealed a novel mutation in SLC12A3 (c.1072del, p.(Ala358Profs*12)). This novel mutation extends the spectrum of known SLC12A3 gene mutations and further supports the allelic heterogeneity of GS.

Keywords: fluid electrolyte and acid-base disturbances; genetics; renal medicine.

Publication types

  • Case Reports

MeSH terms

  • Genetic Markers
  • Genetic Testing
  • Gitelman Syndrome / diagnosis*
  • Gitelman Syndrome / genetics*
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Solute Carrier Family 12, Member 3 / genetics

Substances

  • Genetic Markers
  • SLC12A3 protein, human
  • Solute Carrier Family 12, Member 3